Thea US has announced the upcoming US launch of Zolymbus (bimatoprost ophthalmic gel 0.01%), a preservative-free gel formulation developed for the management of glaucoma.

Zolymbus is a preservative-free gel formulation which is a prostaglandin analog indicated for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertensionis. Designed and developed with a focus on efficacy, tolerability, safety, and convenience, Zolymbus aims to support long-term treatment adherence while addressing the needs of both patients and eye care professionals.

“With the launch of Zolymbus, we are introducing more than a new treatment option—we are delivering an innovative solution designed to improve the experience of glaucoma management for both patients and providers,” said Rob Shilton, head of marketing at Thea US, in a company statement. “This launch reflects our continued commitment to advancing ophthalmic care through meaningful innovation and patient-focused therapies.”

The company stated that Zolymbus will be supported by product availability and patient access initiatives as it enters the US market. 

“Our team is energized by the opportunity ahead,” Mr. Shilton said. “Through strong partnerships with eye care professionals and a continued focus on clinical excellence, we believe Zolymbus has the potential to make a meaningful impact in glaucoma care across the United States.”